glp 1 which company Comparing Ozempic, Wegovy and Other GLP-1 Drugs Market Overview: GLP-1 Agonists and

Patients come to us with a range of chronic wounds, including: Chronic bone infections (osteomyelitis) Circulatory problems and vascular ulcers Compromised skin grafts/flaps Crush injuries Diabetic foot ulcers Injuries from late effects of radiation Non-healing surgical incisions Pressure ulcers Venous stasis ulcers Unlike normal wounds, chronic or traumatic wounds show no significant signs of healing over a period of several weeks

None of the products contained herein are intended to diagnose, treat, cure, or prevent any disease.

NEW & RETURNING PATIENTS We will bill our services to contracted health insurance companies as a courtesy

The market for GLP-1 drugs is expected to reach $100 billion by 2030

Mod Rheumatol (2011) 21(6):60820.10.1007/s10165-011-0455-2 35 Nuche-BerenguerBPortal-NunezSMorenoPGonzalezNAcitoresALopez-HerradonAet alPresence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor